Effects of infliximab therapy on transmural lesions as assessed by magnetic resonance enteroclysis in patients with ileal Crohn's disease

Anti TNF therapy induces mucosal healing in patients with Crohn's disease, but the effects on transmural inflammation in the ileum are not well understood. Magnetic resonance-enteroclysis (MRE) offers excellent imaging of transmural and peri-enteric lesions in Crohn's ileitis and we aimed...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Journal of Crohn's and colitis Ročník 7; číslo 12; s. 950
Hlavní autoři: Van Assche, Gert, Herrmann, Karin A, Louis, Edouard, Everett, Simon M, Colombel, Jean-Frédéric, Rahier, Jean-François, Vanbeckevoort, Dirk, Meunier, Paul, Tolan, Damian, Ernst, Olivier, Rutgeerts, Paul, Vermeire, Séverine, Aerden, Isolde, Oortwijn, Alessandra, Ochsenkühn, Thomas
Médium: Journal Article
Jazyk:angličtina
Vydáno: England 15.12.2013
Témata:
Adult
Anti-Inflammatory Agents, Non-Steroidal - adverse effects
Anti-Inflammatory Agents, Non-Steroidal - therapeutic use
Antibodies, Monoclonal - adverse effects
Antibodies, Monoclonal - therapeutic use
C-Reactive Protein - metabolism
Contrast Media
Crohn Disease - blood
Crohn Disease - drug therapy
Crohn Disease - pathology
Female
Gadolinium
Humans
Ileitis - blood
Ileitis - drug therapy
Ileitis - pathology
Infliximab
Magnetic Resonance Imaging
Male
Middle Aged
Severity of Illness Index
Time Factors
Young Adult
Crohn's disease
Anti-TNF therapy
Complications
Imaging
MR enteroclysis
ISSN:1876-4479, 1876-4479
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Anti TNF therapy induces mucosal healing in patients with Crohn's disease, but the effects on transmural inflammation in the ileum are not well understood. Magnetic resonance-enteroclysis (MRE) offers excellent imaging of transmural and peri-enteric lesions in Crohn's ileitis and we aimed to study its responsiveness to anti TNF therapy. In this multi-center prospective trial, anti TNF naïve patients with ileal Crohn's disease and with increased CRP and contrast enhanced wall thickening received infliximab 5 mg/kg at weeks 0, 2 and 6, and q8 weeks maintenance MRE was performed at baseline, 2 weeks and 6 months and assessed based on a predefined MRE score of severity in ileal Crohn's Disease. Twenty patients were included; of those, 18 patients underwent MRE at week 2 and 15 patients at weeks 2 and 26 as scheduled. Inflammatory components of the MRE index decreased by ≥2 points and by ≥50% at week 26 (primary endpoint) in 40% and 32% of patients (per protocol and intention to treat analysis, respectively). The MRE index improved in 44% at week 2 and in 80% at week 26. Complete absence of inflammatory lesions was observed in 0/18 at week 2 and 13% (2/15) at week 26. The obstructive elements did not change. Clinical and CRP improvement occurred as early as wk 2, but only CDAI correlated with the MRE index. Improvement of MRE occurs from 2 weeks after infliximab therapy onwards and correlates with clinical response but normalization of MRE is rare.
Bibliografie:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ISSN:1876-4479
1876-4479
DOI:10.1016/j.crohns.2013.01.011